BOSTON, June 8 /PRNewswire-FirstCall/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced the results of a survey conducted during its recent webinar entitled "Convergence of Technologies to Simplify Workflow." Perceptive polled biopharmaceutical industry professionals across a broad range of clinical and IT functions about their approaches to the integration of key eClinical systems, such as Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), and Randomization and Trial Supply Management (RTSM) technologies.
Survey results revealed that most respondents (71%) currently have integrated or are in the process of integrating a number of systems toward the goals of improving processes and overall trial data accuracy. A smaller group of respondents (21%) claimed to see the value of integrating their systems, but have not done so to date. Only 8% confirmed that their companies have developed established integration standards to which they expect technology vendors to adhere with regard to key systems.
According to Bill Byrom, Ph.D., Senior Director, Product Strategy, Perceptive Informatics, "The biopharmaceutical industry is increasingly recognizing the value of integrating key systems to enable more effective information flow across functions and organizations involved in executing clinical trials. However, we anticipate that there is a significant opportunity for the industry to implement integration standards and achieve true interoperability across eClinical systems. The realization of a fully integrated environment is expected to streamline workflow and support real-time data interchange to help companies make better, faster decisions and ultimately run trials more efficiently."
During the webinar, Dr. Byrom and Iain Dowlman, Senior Director, eClinical Services at Perceptive Informatics, presented Perceptive's approach to enable the most efficient workflow by simplifying the use of multiple technologies and optimizing them for the way users manage clinical trials. The experts discussed the concept of product convergence, which makes the functionality that exists in one application accessible through another, changing the way technologies can be used together to bring more efficiency to the clinical trial process.
To access the webcast on demand visit: http://www.perceptive.com/News/Webinars/index.html.
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $24 million over the second, third, and fourth quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 as filed with the SEC on May 7, 2010 which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
SOURCE PAREXEL International Corporation